StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
LENZLENZ Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$3.15▼ 0.16%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $98.8MShares out 31.4M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

4
  • 3d agoAfter-hours26.10.22 06:44
    SCHEDULE 13G/AOwnership#●●●

    LENZ Therapeutics, Inc.

    Millennium Management LLC and Israel A. Englander have filed a Schedule 13G regarding the beneficial ownership of LENZ Therapeutics, Inc. common stock. This filing confirms the joint filing agreement among the parties in accordance with Rule 13d-1(k) of the Securities Exchange Act.…more

    $3.15-0.16%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.8Regular26.09.08 22:59
    SCHEDULE 13G/AOwnership

    LENZ Therapeutics, Inc.

    FMR LLC and its affiliates have filed a Schedule 13G regarding their beneficial ownership of LENZ Therapeutics common stock. The filing confirms their collective ownership position as of August 31, 2026, and outlines the voting control structure involving Abigail P. Johnson and the FMR LLC group.…more

    $3.15-0.16%vs prev close
    View filingShare
  • 8.11After-hours26.08.12 05:13
    10-QEarnings

    LENZ Therapeutics, Inc.

    LENZ Therapeutics는 2026년 2분기 실적 보고를 통해 사외이사 보상 정책을 개정하고 주식 기반 보상 체계를 구체화했습니다. 2026년 8월 5일 기준 발행 주식 수는 31,420,343주이며, 회사는 VIZZ 제품의 상업화 및 임상 개발을 지속하고 있습니다.…more

    $3.15-0.16%vs prev close
    View filingShare

3 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 8.11After-hours26.08.12 05:05
    Bullish#●●●#●●●#●●●

    렌즈 테라퓨틱스, 2분기 실적 발표 및 VIZZ 성장세 강조

    렌즈 테라퓨틱스는 노안 치료제 VIZZ의 매출 증가와 함께 텔레헬스 채널 도입 등 시장 확대 전략을 발표했습니다. 초기 처방 환자들의 높은 재구매율을 바탕으로 글로벌 파트너십을 통한 해외 시장 진출도 가속화하고 있습니다.…more

    $3.15-0.16%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 8.4After-hours26.08.05 05:05

    ●●●●●●●● ●●●●● ●●●●●●

    렌즈 테라퓨틱스가 오는 8월 11일 2분기 재무 실적과 주요 기업 성과를 발표하는 웹캐스트를 진행합니다. 이번 발표를 통해 노안 치료제 VIZZ의 상업화 진행 상황과 향후 사업 전략이 공개될 예정입니다.…more

    $3.15-0.16%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →